Stereotaxis Inc (STXS) Stock Price, Quote & News

Company Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is design...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 314 678 6100

Website: www.stereotaxis.com

Address:

710 North Tucker Boulevard, Suite 110, Saint Louis, United States

trigger_finger Feb. 24 at 3:17 AM

$STXS 5 Sessions at HRS now, PFA and Stereotaxis! While this is not going to move the stock short term, this is underlying bullishness for future adoption.

0 · Reply

trigger_finger Feb. 24 at 3:09 AM

$STXS So Dr. Andrea Natale is now a supporter of STXS? I hadn't even peeled back the onion in this area. He is actually presenting PFA and the use of RMN at HRS this year. He is now a strong advocate of Stereotaxis now, and while apparently this has been the case for quite some time (best I can find is late 2016), he is well respected in the PFA arena, and him talking specifically about the use of Genesis with PFA is a big feather in the cap here, considering they have to have PFA, no option. Very good to see. Looks like 2.40 in the cards short term as well.......

0 · Reply

trigger_finger Feb. 23 at 8:02 PM

$STXS $IREN Robots and Datacenters.... will take it today.

0 · Reply

alexpitti Feb. 22 at 4:26 PM

jack hughes my boy wins it $STXS $DCTH $ABEO

1 · Reply

_Not_Sure_ Feb. 20 at 8:08 PM

$STXS buy every morning, sell at lunch. Infinite money machine!

2 · Reply

trigger_finger Feb. 20 at 6:34 PM

$STXS At least 2 confirmed sessions at HRS will discuss Genesis X and PFA. Magic was a band aid, even if superior to JNJ catheter, Sweep speeds up the procedure and makes a complete robotic experience. PFA is the future, and desired catheter, so good to see this is going to be the focus of the launch/event. While as unlikely as it maybe, its possible PFA can get approval this year.

0 · Reply

DipFalcon Feb. 20 at 5:05 PM

$STXS Stereotaxis develops robotic surgical systems. Adoption depends on hospital capex. Long sales cycles increase risk.

0 · Reply

trigger_finger Feb. 19 at 3:13 AM

$STXS These companies have confirmed extended Sunday sessions at HRS in April. While STXS was expected, this should confirm launch is a go at HRS, and as you can see, very small select group. Feb. 20, we'll see how many speakers/Dr's they line up for the event.

0 · Reply

jacksonjohn750 Feb. 18 at 12:54 PM

$STXS this is our year to say next year is our year

1 · Reply

CipherBroker Feb. 18 at 7:52 AM

$STXS Stereotaxis provides robotic surgical systems, facing long-cycle capital equipment sales requiring strong clinical evidence [citation:historical].

0 · Reply

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

Feb 9, 2026, 8:06 AM EST - 14 days ago

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Jan 6, 2026, 8:01 AM EST - 6 weeks ago

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Nov 24, 2025, 8:58 AM EST - 3 months ago

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 11, 2025, 7:51 PM EST - 3 months ago

Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 4:01 PM EST - 3 months ago

Stereotaxis Reports 2025 Third Quarter Financial Results

Nov 10, 2025, 4:05 PM EST - 3 months ago

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

Oct 21, 2025, 9:00 AM EDT - 4 months ago

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

Oct 15, 2025, 7:32 AM EDT - 4 months ago

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

Oct 13, 2025, 7:34 AM EDT - 4 months ago

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias

Sep 22, 2025, 7:56 AM EDT - 5 months ago

Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

Sep 2, 2025, 8:08 AM EDT - 6 months ago

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

Sep 2, 2025, 7:51 AM EDT - 6 months ago

Stereotaxis to Present at Upcoming Investor Conferences

Aug 28, 2025, 7:47 AM EDT - 6 months ago

Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

Aug 8, 2025, 1:24 PM EDT - 7 months ago

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 7 months ago

Stereotaxis Reports 2025 Second Quarter Financial Results

Jul 28, 2025, 7:48 AM EDT - 7 months ago

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 17, 2025, 8:32 AM EDT - 7 months ago

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

Jul 6, 2025, 2:13 AM EDT - 8 months ago

Stereotaxis: Recurring Revenue Inflection

Jul 1, 2025, 9:00 AM EDT - 8 months ago

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

May 12, 2025, 7:04 PM EDT - 10 months ago

Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 10 months ago

Stereotaxis Reports 2025 First Quarter Financial Results

Apr 22, 2025, 7:00 AM EDT - 10 months ago

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

Mar 19, 2025, 8:01 AM EDT - 1 year ago

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Mar 10, 2025, 8:02 AM EDT - 1 year ago

Stereotaxis to Present at 37th Annual Roth Conference

Mar 7, 2025, 9:10 AM EST - 1 year ago

Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn

Mar 3, 2025, 10:34 AM EST - 1 year ago

Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:32 AM EST - 1 year ago

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Mar 3, 2025, 7:31 AM EST - 1 year ago

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

Mar 3, 2025, 7:30 AM EST - 1 year ago

Stereotaxis Reports 2024 Full Year Financial Results

Feb 25, 2025, 8:03 AM EST - 1 year ago

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

Feb 14, 2025, 10:41 AM EST - 1 year ago

Stock Market Sleeps On Stereotaxis MAGiC CE Mark

Feb 3, 2025, 4:05 PM EST - 1 year ago

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Jan 30, 2025, 8:09 AM EST - 1 year ago

Stereotaxis Announces First GenesisX Robotic System Order

Jan 27, 2025, 8:00 AM EST - 1 year ago

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

Jan 14, 2025, 7:21 AM EST - 1 year ago

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

Dec 9, 2024, 7:25 AM EST - 1 year ago

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

Dec 2, 2024, 8:45 AM EST - 1 year ago

Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

Dec 2, 2024, 5:03 AM EST - 1 year ago

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025

Nov 26, 2024, 8:28 AM EST - 1 year ago

Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 8:21 AM EST - 1 year ago

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

Nov 20, 2024, 8:18 AM EST - 1 year ago

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Nov 11, 2024, 7:03 PM EST - 1 year ago

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:02 PM EST - 1 year ago

Stereotaxis Reports 2024 Third Quarter Financial Results

Oct 21, 2024, 8:41 AM EDT - 1 year ago

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Sep 3, 2024, 8:53 AM EDT - 1 year ago

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

Aug 25, 2024, 7:22 PM EDT - 1 year ago

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

Aug 12, 2024, 11:33 PM EDT - 1 year ago

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

trigger_finger Feb. 24 at 3:17 AM

$STXS 5 Sessions at HRS now, PFA and Stereotaxis! While this is not going to move the stock short term, this is underlying bullishness for future adoption.

0 · Reply

trigger_finger Feb. 24 at 3:09 AM

0 · Reply

trigger_finger Feb. 23 at 8:02 PM

$STXS $IREN Robots and Datacenters.... will take it today.

0 · Reply

alexpitti Feb. 22 at 4:26 PM

jack hughes my boy wins it $STXS $DCTH $ABEO

1 · Reply

_Not_Sure_ Feb. 20 at 8:08 PM

$STXS buy every morning, sell at lunch. Infinite money machine!

2 · Reply

trigger_finger Feb. 20 at 6:34 PM

0 · Reply

DipFalcon Feb. 20 at 5:05 PM

$STXS Stereotaxis develops robotic surgical systems. Adoption depends on hospital capex. Long sales cycles increase risk.

0 · Reply

trigger_finger Feb. 19 at 3:13 AM

0 · Reply

jacksonjohn750 Feb. 18 at 12:54 PM

$STXS this is our year to say next year is our year

1 · Reply

CipherBroker Feb. 18 at 7:52 AM

$STXS Stereotaxis provides robotic surgical systems, facing long-cycle capital equipment sales requiring strong clinical evidence [citation:historical].

0 · Reply

_Not_Sure_ Feb. 17 at 7:09 PM

$STXS why the boost in SP today? Come on all you $STXS experts. I’m ready for your theories.

2 · Reply

jacksonjohn750 Feb. 17 at 1:31 PM

$STXS Just had a chat with an EP chap and he confirmed it............................................................................................................................................................................................................................................................................................... This will not move until Pitti sells.

1 · Reply

DecoderRing Feb. 15 at 2:55 PM

$STXS Externally guided magnets to target kidney stones. Hey David, reach out to them and offer Genesis.

3 · Reply

Eddypgil Feb. 13 at 6:14 PM

$STXS I’m betting that sales of magic catheter will begin trending higher . Nice margins on those

1 · Reply

Eddypgil Feb. 13 at 6:09 PM

$STXS I would do a convertible of $10 million 2% interest convertible at a price of $6

0 · Reply

jacksonjohn750 Feb. 12 at 11:55 PM

$STXS are they l are expected to receive an additional $4 million from a second closing of a private placement? If so, it would bring their pro-forma cash to about $14.5 million.

1 · Reply

trigger_finger Feb. 12 at 3:51 AM

$STXS

0 · Reply

jacksonjohn750 Feb. 11 at 12:16 AM

$STXS I think they will have another shitty quarter... maybe a good time to pick up on that dip

1 · Reply

Georges8792 Feb. 10 at 9:01 PM

$STXS https://www.linkedin.com/posts/stereotaxis_afsymposium-roboticep-activity-7427068249911226368-2MVz?utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_source=social_share_send&utm_campaign=share_via

0 · Reply

Georges8792 Feb. 10 at 4:57 PM

$STXS https://www.linkedin.com/posts/klinikum-f-rth_mit-der-er%C3%B6ffnung-eines-neuen-komplett-sterilen-ugcPost-7427017473213947904-M-Jz?utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_source=social_share_send&utm_campaign=share_via

0 · Reply

Eddypgil Feb. 9 at 6:57 PM

$STXS I heard from a source that APT will be manufacturing magic catheters for use by US hospitals

0 · Reply

Eddypgil Feb. 9 at 5:13 PM

$STXS today feels like stock may be turning around finally

0 · Reply

Market Cap	193.18M
Revenue (ttm)	26.92M
Net Income (ttm)	-24.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89.34%
Debt to Equity Ratio	0.00

Volume	460,200
Avg Vol	532,076
Day's Range	N/A - N/A
Shares Out	93.33M
Stochastic %K	83%
Beta	1.44
Analysts	Strong Sell
Price Target	$4.20